רמיקד

国家: 以色列

语言: 希伯来文

来源: Ministry of Health

有效成分:

INFLIXIMAB 100 MG/VIAL

可用日期:

J-C HEALTH CARE LTD

ATC代码:

L04AA12

药物剂型:

POWDER FOR CONCENTRATE FOR INFUSION

给药途径:

I.V

厂商:

JANSSEN BIOLOGICS, BV, THE NETHERLAND

治疗组:

INFLIXIMAB

疗效迹象:

- Adult :Crohn's disease: Treatment of severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy -Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

授权日期:

2010-01-01